[1] van Boven JF, de Boer PT, Postma MJ, et al. Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab. 2013. in press.
[2] Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469-480.
[3] Viaene L, Behets GJ, Claes K, et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant. 2013. in press.
[4] Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19-26.
[5] Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am. 2013;44(2):125-135.
[6] Yee AJ, Raje NS. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging. 2012;7:331-338.
[7] Lim V, Clarke BL. New therapeutic targets for osteoporosis: beyond denosumab. Maturitas. 2012;73(3):269-272.
[8] 李梅,周学瀛.骨质疏松症治疗新进展[J].国际内分泌代谢杂志, 2011,31(6):386-389.
[9] Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.
[10] Weidauer SE, Schmieder P, Beerbaum M, et al. NMR structure of the Wnt modulator protein Sclerostin. Biochem Biophys Res Commun. 2009;380(1):160-165.
[11] Moester MJ, Papapoulos SE, Löwik CW, et al. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010;87(2):99-107.
[12] Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006;21(11): 1738-1749.
[13] van Dinther M, Zhang J, Weidauer SE, et al. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin- mediated antagonism of Wnt/LRP6 signaling. PLoS One. 2013;8(4):e62295.
[14] Balemans W, Van Hul W. Human genetics of SOST. J Musculoskelet Neuronal Interact. 2006;6(4):355-356.
[15] Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19(13):1842-1844.
[16] 孙静,夏维波,姜艳.骨硬化蛋白:一个治疗骨质疏松的新靶点[J].国际内分泌代谢杂志,2010,30(4):236-238.
[17] Drüeke TB, Lafage-Proust MH. Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol. 2011; 6(4):700-703.
[18] Tu X, Rhee Y, Condon KW, et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012;50(1):209-217.
[19] Sims NA. Building bone with a SOST-PTH partnership. J Bone Miner Res. 2010;25(2):175-177.
[20] Jawad MU, Fritton KE, Ma T, et al. Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. J Orthop Res. 2013;31(1):155-163.
[21] Mödder UI, Clowes JA, Hoey K, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26(1):27-34.
[22] Zhu D, Mackenzie NC, Millán JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One. 2011;6(5):e19595.
[23] Román-García P, Carrillo-López N, Fernández-Martín JL, et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone. 2010;46(1):121-128.
[24] Gkotzamanidou M, Dimopoulos MA, Kastritis E, et al. Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opin Ther Targets. 2012;16(8):761-769.
[25] Ryan ZC, Ketha H, McNulty MS, et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A. 2013;110(15):6199-6204.
[26] Gamie Z, Korres N, Leonidou A, et al. Sclerostin monoclonal antibodies on bone metabolism and fracture healing. Expert Opin Investig Drugs. 2012;21(10):1523-1534.
[27] Okazaki R. Anti-sclerostin antibodies. Clin Calcium. 2011; 21(1):94-98.
[28] Wei W, Zeve D, Suh JM, et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol. 2011;31(23):4706-4719.
[29] Collette NM, Genetos DC, Murugesh D, et al. Genetic evidence that SOST inhibits WNT signaling in the limb. Dev Biol. 2010;342(2):169-179.
[30] Silverman SL. Sclerostin. J Osteoporos. 2010;2010:941419.
[31] Semenov MV, He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem. 2006;281(50):38276-38284.
[32] Monroe DG, McGee-Lawrence ME, Oursler MJ, et al. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012;492(1):1-18.
[33] Mosekilde L, Tørring O, Rejnmark L. Emerging anabolic treatments in osteoporosis. Curr Drug Saf. 2011;6(2):62-74.
[34] Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883-19887.
[35] ten Dijke P, Krause C, de Gorter DJ, et al. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008;90 Suppl 1:31-35.
[36] Papapoulos SE. Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis. 2011;70 Suppl 1:i119-122.
[37] Atkins GJ, Rowe PS, Lim HP, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM- dependent mechanism. J Bone Miner Res. 2011;26(7):1425-1436.
[38] Salmon B, Bardet C, Khaddam M, et al. MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia. PLoS One. 2013;8(2):e56749.
[39] Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr. 2012;22(1):61-86.
[40] Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther. 2011;11(1):117-127.
[41] Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-588.
[42] van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007; 22(1): 19-28.
[43] Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009;24 (10):1662-1671.
[44] Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860-869.
[45] Agholme F, Isaksson H, Li X, et al. Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop. 2011;82(5):628-632.
[46] Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26(5):1012-1021.
[47] Tian X, Jee WS, Li X, et al. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011; 48(2):197-201.
[48] Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948-959.
[49] Tian X, Setterberg RB, Li X, et al. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010;47(3):529-533.
[50] Smith SY, Jolette J, Turner CH. Skeletal health: primate model of postmenopausal osteoporosis. Am J Primatol. 2009; 71(9):752-765.
[51] Lane NE, Silverman SL. Anabolic therapies. Curr Osteoporos Rep. 2010;8(1):23-27.
[52] Marenzana M, Greenslade K, Eddleston A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum. 2011;63(8):2385-2395.
[53] Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011; 152(9):3312-3322.
[54] Chen XX, Baum W, Dwyer D, et al. Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis. 2013. in press. |